mar vn RIEFOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USETest DetailsGeneGenotypePhenotypeAlleles TestedCYP2C19*2/*7Poor Metabolizer*2, *3, *4, *48, *5, *6, *7, *8, *9, *17CYP2D6*1/"4Intermediate Metabolizer*2, *3, *4, *4M, *6, *7, *8, *9, *10, *12, *14A, *148, *17, *29,*35, *41СҮРЗАS*3/"3Poor Metabolizer*1D, *2, *3, *3B, *3C, "6, *7, *8, *9СҮРЗА4*1/*1Normal Metabolizer*18, *2, *3, *12, *17, *22VKORCI-1639GA G/AIntermediate Warfarin Sensitivity-1639GACYP4F2*1/3Decreased Function*2, *3*2, *3, *4, *5, *6, *11*6, *9CYP2C9*1/*1Normal MetabolizerCYP2B6*1/1Normal MetabolizerNormal Metabolizer - HigherInducibilityCYPIA2*1F/*1F*1C, *1D, *1F, *1K, *1L, *1V, *1WSLCOIB1521TC T/TNormal Function521TC, 388A GCFTRFS08del/RS53XNegativeNumerousDPYD*1/*1Normal MetabolizerNumerous*2, *3A, *3B, *3C, *4*2, *3, *4, *5, *6, *7, *8, *9ТРМТ*1/"3A*1/1Intermediate MetabolizerNUDT15Normal MetabolizerUGTIAI*1/*36Normal Metabolizer*6, *27, *28, *36, *37, *60, *80G6PD Bangkok or Bangkok/BangkokDeficient with CNSHANumerousAdditional Test Results (added to this original report)HLA-B*15:02 negative/negative NegativeHLA-B'57:01 negative/negative NegativeHLA-B'58:01 negative/negative NegativeHLA-A*31:01 negative/negative Negative Case of Antiplatelet Therapy:Mr. Mark Johnson (MJ) is a 58-year-old Caucasian male who has just undergone percutaneouscoronary intervention with coronary artery stent placement. MJ has a history of diabetes andhypertension. MJ is placed on dual-antiplatelet therapy, including aspirin and prasugrel.Pharmacogenetic testing was performed and the results report is available (below, next page). Theprimary care prescriber wishes to change prasugrel to clopidogrel and you are consulted on thiscase. What is your recommendation for MJ? Explain in detail and based on scientific evidence.

Question

mar vn RIEFOR ACADEMIC PURPOSES ONLY - NOT FOR CLINICAL USETest DetailsGeneGenotypePhenotypeAlleles TestedCYP2C19*2/*7Poor Metabolizer*2, *3, *4, *48, *5, *6, *7, *8, *9, *17CYP2D6*1/&#34;4Intermediate Metabolizer*2, *3, *4, *4M, *6, *7, *8, *9, *10, *12, *14A, *148, *17, *29,*35, *41СҮРЗАS*3/&#34;3Poor Metabolizer*1D, *2, *3, *3B, *3C, &#34;6, *7, *8, *9СҮРЗА4*1/*1Normal Metabolizer*18, *2, *3, *12, *17, *22VKORCI-1639G>A G/AIntermediate Warfarin Sensitivity-1639G>ACYP4F2*1/3Decreased Function*2, *3*2, *3, *4, *5, *6, *11*6, *9CYP2C9*1/*1Normal MetabolizerCYP2B6*1/1Normal MetabolizerNormal Metabolizer - HigherInducibilityCYPIA2*1F/*1F*1C, *1D, *1F, *1K, *1L, *1V, *1WSLCOIB1521T>C T/TNormal Function521T>C, 388A> GCFTRFS08del/RS53XNegativeNumerousDPYD*1/*1Normal MetabolizerNumerous*2, *3A, *3B, *3C, *4*2, *3, *4, *5, *6, *7, *8, *9ТРМТ*1/&#34;3A*1/1Intermediate MetabolizerNUDT15Normal MetabolizerUGTIAI*1/*36Normal Metabolizer*6, *27, *28, *36, *37, *60, *80G6PD Bangkok or Bangkok/BangkokDeficient with CNSHANumerousAdditional Test Results (added to this original report)HLA-B*15:02 negative/negative NegativeHLA-B'57:01 negative/negative NegativeHLA-B'58:01 negative/negative NegativeHLA-A*31:01 negative/negative Negative Case of Antiplatelet Therapy:Mr. Mark Johnson (MJ) is a 58-year-old Caucasian male who has just undergone percutaneouscoronary intervention with coronary artery stent placement. MJ has a history of diabetes andhypertension. MJ is placed on dual-antiplatelet therapy, including aspirin and prasugrel.Pharmacogenetic testing was performed and the results report is available (below, next page). Theprimary care prescriber wishes to change prasugrel to clopidogrel and you are consulted on thiscase. What is your recommendation for MJ? Explain in detail and based on scientific evidence.

Accepted Answer

Hypertension is a lifestyle disorder in which the blood exerts higher than normal (120/80 mmHg)…